Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters











Database
Language
Publication year range
1.
Maturitas ; 69(4): 354-8, 2011 Aug.
Article in English | MEDLINE | ID: mdl-21684096

ABSTRACT

OBJECTIVE: To compare, whether women with menorrhagia, treated with either hysterectomy or LNG-IUS, differ in their cardiovascular risk profile during 10-year follow-up. STUDY DESIGN: A total of 236 women were randomized to treatment by hysterectomy (n=117) or LNG-IUS (n=119). Their cardiovascular risk factors were analyzed at baseline, at 5 years, and at 10 years. As 55 originally randomized to the LNG-IUS group had hysterectomy during the follow-up, all analyzes were performed by actual treatment modality. MAIN OUTCOME MEASURES: Waist circumference, body-mass index (BMI), blood pressure, and the levels of blood lipids, serum high-sensitivity CRP (hsCRP) and tumor necrosis factor alpha (TNF-α) were measured, and the use of medication for hypertension, diabetes, hypercholesterolemia, and ischemic heart disease was analyzed. RESULTS: After 5 years, an increase in the use of diabetes medication during the follow-up was only detected in the hysterectomy group (from 1.7% to 6.7%, P=0.008 vs from 5.1% to 8.4%, P=0.08), as well as they had significantly higher serum levels of TNF-α (108.59 pg/ml vs 49.02 pg/ml, P=0.001) and hsCRP (1.55 µg/ml vs 0.78 µg/ml, P=0.038) at 5- and 10-years. There was no difference between the groups in the use of cardiovascular medication, neither was there difference in blood pressure, waist circumference, BMI, or concentrations of blood lipids. CONCLUSIONS: Hysterectomy seems to be associated with increased levels of serum inflammatory markers and increased diabetes medication, which in turn, may predispose individual to future cardiovascular events.


Subject(s)
Cardiovascular Diseases/etiology , Diabetes Mellitus/etiology , Hysterectomy/adverse effects , Inflammation/complications , Levonorgestrel/adverse effects , Menorrhagia/therapy , Progestins/adverse effects , Adult , C-Reactive Protein/metabolism , Cardiovascular Diseases/blood , Diabetes Mellitus/blood , Diabetes Mellitus/drug therapy , Female , Follow-Up Studies , Humans , Hypoglycemic Agents/therapeutic use , Inflammation/blood , Intrauterine Devices, Medicated , Levonorgestrel/therapeutic use , Menorrhagia/blood , Middle Aged , Progestins/therapeutic use , Risk Factors , Tumor Necrosis Factor-alpha/blood
SELECTION OF CITATIONS
SEARCH DETAIL